1. WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. 08.11.2021. https://covid19.who.int/. Accessed 8 Nov 2021.
2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395:497–506. doi:10.1016/S0140-6736(20)30183-5.
3. Shashaty MGS, Reilly JP, Faust HE, Forker CM, Ittner CAG, Zhang PX, et al. Plasma receptor interacting protein kinase-3 levels are associated with acute respiratory distress syndrome in sepsis and trauma: a cohort study. Crit Care. 2019;23:235. doi:10.1186/s13054-019-2482-x.
4. Vucur M, Roderburg C, Kaiser L, Schneider AT, Roy S, Loosen SH, et al. Elevated Serum Levels of Mixed Lineage Kinase Domain-Like Protein Predict Survival of Patients during Intensive Care Unit Treatment. Dis Markers. 2018;2018:1983421. doi:10.1155/2018/1983421.
5. Qin C, Sai X, Qian X, Wu Y, Zou L, Wang H, et al. Close Relationship between cIAP2 and Human ARDS Induced by Severe H7N9 Infection. Biomed Res Int. 2019;2019:2121357. doi:10.1155/2019/2121357.
6. Yu X, Mao M, Liu X, Shen T, Li T, Yu H, et al. A cytosolic heat shock protein 90 and co-chaperone p23 complex activates RIPK3/MLKL during necroptosis of endothelial cells in acute respiratory distress syndrome. J Mol Med (Berl). 2020;98:569–83. doi:10.1007/s00109-020-01886-y.
7. Ma KC, Schenck EJ, Siempos II, Cloonan SM, Finkelsztein EJ, Pabon MA, et al. Circulating RIPK3 levels are associated with mortality and organ failure during critical illness. JCI Insight 2018. doi:10.1172/jci.insight.99692.
8. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford M, Chan FK-M. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009;137:1112–23. doi:10.1016/j.cell.2009.05.037.
9. Li J, McQuade T, Siemer AB, Napetschnig J, Moriwaki K, Hsiao Y-S, et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012;150:339–50. doi:10.1016/j.cell.2012.06.019.
10. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell. 2009;137:1100–11. doi:10.1016/j.cell.2009.05.021.
11. Wang H, Sun L, Su L, Rizo J, Liu L, Wang L-F, et al. Mixed lineage kinase domain-like protein MLKL causes necrotic membrane disruption upon phosphorylation by RIP3. Molecular Cell. 2014;54:133–46. doi:10.1016/j.molcel.2014.03.003.
12. Duprez L, Takahashi N, van Hauwermeiren F, Vandendriessche B, Goossens V, Vanden Berghe T, et al. RIP kinase-dependent necrosis drives lethal systemic inflammatory response syndrome. Immunity. 2011;35:908–18. doi:10.1016/j.immuni.2011.09.020.
13. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature. 2002;418:191–5. doi:10.1038/nature00858.
14. Simpson J, Loh Z, Ullah MA, Lynch JP, Werder RB, Collinson N, et al. Respiratory Syncytial Virus Infection Promotes Necroptosis and HMGB1 Release by Airway Epithelial Cells. Am J Respir Crit Care Med. 2020;201:1358–71. doi:10.1164/rccm.201906-1149OC.
15. Qing DY, Conegliano D, Shashaty MGS, Seo J, Reilly JP, Worthen GS, et al. Red blood cells induce necroptosis of lung endothelial cells and increase susceptibility to lung inflammation. Am J Respir Crit Care Med. 2014;190:1243–54. doi:10.1164/rccm.201406-1095OC.
16. Bianchi ME, Beltrame M, Paonessa G. Specific recognition of cruciform DNA by nuclear protein HMG1. Science. 1989;243:1056–9. doi:10.1126/science.2922595.
17. Catez F, Yang H, Tracey KJ, Reeves R, Misteli T, Bustin M. Network of dynamic interactions between histone H1 and high-mobility-group proteins in chromatin. Mol Cell Biol. 2004;24:4321–8. doi:10.1128/mcb.24.10.4321-4328.2004.
18. Lange SS, Mitchell DL, Vasquez KM. High mobility group protein B1 enhances DNA repair and chromatin modification after DNA damage. Proc Natl Acad Sci U S A. 2008;105:10320–5. doi:10.1073/pnas.0803181105.
19. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, Marchis F de, et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med. 2012;209:1519–28. doi:10.1084/jem.20120189.
20. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000;192:565–70. doi:10.1084/jem.192.4.565.
21. Del Valle DM, Kim-Schulze S, Huang H-H, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–43. doi:10.1038/s41591-020-1051-9.
22. Coleman LG, Maile R, Jones SW, Cairns BA, Crews FT. HMGB1/IL-1β complexes in plasma microvesicles modulate immune responses to burn injury. PLoS One. 2018;13:e0195335. doi:10.1371/journal.pone.0195335.
23. Hreggvidsdottir HS, Ostberg T, Wähämaa H, Schierbeck H, Aveberger A-C, Klevenvall L, et al. The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation. J Leukoc Biol. 2009;86:655–62. doi:10.1189/jlb.0908548.
24. Nakamura T, Sato E, Fujiwara N, Kawagoe Y, Maeda S, Yamagishi S. Increased levels of soluble receptor for advanced glycation end products (sRAGE) and high mobility group box 1 (HMGB1) are associated with death in patients with acute respiratory distress syndrome. Clinical Biochemistry. 2011;44:601–4. doi:10.1016/j.clinbiochem.2010.12.014.
25. Schenk B, Fulda S. Reactive oxygen species regulate Smac mimetic/TNFα-induced necroptotic signaling and cell death. Oncogene. 2015;34:5796–806. doi:10.1038/onc.2015.35.
26. Zhang D-W, Shao J, Lin J, Zhang N, Lu B-J, Lin S-C, et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science. 2009;325:332–6. doi:10.1126/science.1172308.
27. Ayala JC, Grismaldo A, Aristizabal-Pachon AF, Mikhaylenko EV, Nikolenko VN, Mikhaleva LM, et al. Mitochondrial Dysfunction In Intensive Care Unit Patients. Current pharmaceutical design 2020. doi:10.2174/1381612826666201207112931.
28. Kluge S, Janssens U, Welte T, Weber-Carstens S, Schälte G, Spinner CD, et al. 113-001LGl_S3_Empfehlungen-zur-stationaeren-Therapie-von-Patienten-mit-COVID-19__2021-05.
29. R: The R Project for Statistical Computing.
30. Max Kuhn (2020). caret: Classification and Regression Training. R package version 6.0-86.
31. Nakamura H, Kinjo T, Arakaki W, Miyagi K, Tateyama M, Fujita J. Serum levels of receptor-interacting protein kinase-3 in patients with COVID-19. Crit Care. 2020;24:484. doi:10.1186/s13054-020-03209-6.
32. Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–24. doi:10.1126/science.abc6027.
33. Chen R, Huang Y, Quan J, Liu J, Wang H, Billiar TR, et al. HMGB1 as a potential biomarker and therapeutic target for severe COVID-19. Heliyon. 2020;6:e05672. doi:10.1016/j.heliyon.2020.e05672.
34. Chen L, Long X, Xu Q, Tan J, Wang G, Cao Y, et al. Elevated serum levels of S100A8/A9 and HMGB1 at hospital admission are correlated with inferior clinical outcomes in COVID-19 patients. Cell Mol Immunol. 2020;17:992–4. doi:10.1038/s41423-020-0492-x.
35. Wolfson RK, Chiang ET, Garcia JGN. HMGB1 induces human lung endothelial cell cytoskeletal rearrangement and barrier disruption. Microvasc Res. 2011;81:189–97. doi:10.1016/j.mvr.2010.11.010.
36. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. The Lancet. 2020;395:1417–8. doi:10.1016/S0140-6736(20)30937-5.
37. Huang W, Liu Y, Li L, Zhang R, Liu W, Wu J, et al. HMGB1 increases permeability of the endothelial cell monolayer via RAGE and Src family tyrosine kinase pathways. Inflammation. 2012;35:350–62. doi:10.1007/s10753-011-9325-5.
38. RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet. 2021;397:1637–45. doi:10.1016/S0140-6736(21)00676-0.
39. Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers inflammatory responses and cell death through caspase-8 activation. Signal Transduct Target Ther. 2020;5:235. doi:10.1038/s41392-020-00334-0.
40. Riebeling T, Jamal K, Wilson R, Kolbrink B, Samson-Himmelstjerna FA von, Moerke C, et al. Primidone blocks RIPK1-driven cell death and inflammation. Cell Death Differ. 2020;28:1610–1626. doi:10.1038/s41418-020-00690-y.
41. Feng L, Yin YY, Liu CH, Xu KR, Li QR, Wu JR, Zeng R. Proteome-wide Data Analysis Reveals Tissue-specific Network Associated with SARS-CoV-2 Infection. J Mol Cell Biol. 2021;12:946–57. doi:10.1093/jmcb/mjaa033.
42. Codo AC, Davanzo GG, Monteiro LdB, Souza GF de, Muraro SP, Virgilio-da-Silva JV, et al. Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis. Cell metabolism. 2020;32:437-446.e5. doi:10.1016/j.cmet.2020.07.007.
43. Miripour ZS, Sarrami-Forooshani R, Sanati H, Makarem J, Taheri MS, Shojaeian F, et al. Real-time diagnosis of reactive oxygen species (ROS) in fresh sputum by electrochemical tracing; correlation between COVID-19 and viral-induced ROS in lung/respiratory epithelium during this pandemic. Biosens Bioelectron. 2020;165:112435. doi:10.1016/j.bios.2020.112435.
44. Tian M, Liu W, Li X, Zhao P, Shereen MA, Zhu C, et al. HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. Signal Transduct Target Ther. 2021;6:308. doi:10.1038/s41392-021-00726-w.
45. Clough E, Chean KT, Inigo J, Tubbesing KE, Chandra D, Chaves L, et al. Mitochondrial Dynamics in SARS-COV2 Spike Protein Treated Human Microglia: Implications for Neuro-COVID. J Neuroimmune Pharmacol. 2021:1–15. doi:10.1007/s11481-021-10015-6.
46. Andargie TE, Tsuji N, Seifuddin F, Jang MK, Yuen PS, Kong H, et al. Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight 2021. doi:10.1172/jci.insight.147610.
47. Kahn R, Schmidt T, Golestani K, Mossberg A, Gullstrand B, Bengtsson AA, Kahn F. Mismatch between circulating cytokines and spontaneous cytokine production by leukocytes in hyperinflammatory COVID-19. J Leukoc Biol. 2021;109:115–20. doi:10.1002/JLB.5COVBCR0720-310RR.
48. Zhou Z, Ren L, Zhang L, Zhong J, Xiao Y, Jia Z, et al. Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients. Cell Host Microbe. 2020;27:883-890.e2. doi:10.1016/j.chom.2020.04.017.
49. Wang L, Wang T, Li H, Liu Q, Zhang Z, Xie W, et al. Receptor Interacting Protein 3-Mediated Necroptosis Promotes Lipopolysaccharide-Induced Inflammation and Acute Respiratory Distress Syndrome in Mice. PLOS ONE. 2016;11:e0155723. doi:10.1371/journal.pone.0155723.
50. Szabo PA, Dogra P, Gray JI, Wells SB, Connors TJ, Weisberg SP, et al. Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. Immunity. 2021;54:797-814.e6. doi:10.1016/j.immuni.2021.03.005.
51. Cavalli G, Luca G de, Campochiaro C, Della-Torre E, Ripa M, Canetti D, et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. The Lancet Rheumatology. 2020;2:e325-e331. doi:10.1016/S2665-9913(20)30127-2.